|
| |
| Eisai Co., Ltd. (Tokyo, Japan, President: Haruo Naito) and Bracco-Eisai Co., Ltd. (Tokyo, Japan, President: Toshio Matsumoto) decided to withdraw the new drug application (NDA) of E7155 (gadobenate meglumine), since new indications are emerging for the product and additional clinical data was necessary to complete the targeting product competitive risk/benefit profile. The product is currently marketed in other countries, and both companies are discussing a future development plan in Japan.
MRI Contrast Agents:
Contact Information
MAIL
Bracco Eisai Co., Ltd.
2-6, Kohinata 4-chome, Bunkyo-ku, Tokyo, 112-0006
| |
|
| • View the DATABASE results for 'Bracco-Eisai Co., Ltd.' (2).
| |
| | |